What happens when people stop taking GLP-1 weight-loss injections like Ozempic, Wegovy or Mounjaro? Do they regain weight, switch to another medication or consider bariatric surgery? A new study published in The Lancet's eClinicalMedicine examined that what people do after their initial GLP-1 treatment can make a significant difference in their long-term weight outcomes.Maintaining Weight After GLP-1 TreatmentAlso read: World Diabetes Day: Why Some Diabetes Patients May Not Be Suitable For GLP-1 Treatment, Experts ExplainResearchers at Cleveland Clinic examined health records from 20,486 patients who had taken semaglutide or tirzepatide injections for at least three months. They compared five weight loss maintenance over a two-year period: continuing the original weight loss medication, switching between the two drugs, moving to another obesity medication, undergoing bariatric surgery or stopping treatment altogether without pursuing another option. After two years, the average weight reductions were:Bariatric surgery: Approximately 28% of body weight.Switching between semaglutide and tirzepatide: 16%.Continuing the original GLP-1 medication: Nearly 11%.Switching to another obesity medication: Approximately 8%.Stopping treatment without further intervention: Approximately 4%.These results indicate that discontinuing GLP-1 treatment does not mean all the lost weight will come back. But patients who stopped treatment without another medical or surgical intervention experienced the lowest success in keeping the weight off. The study also found that the outcomes of switching depended on which medication patients were taking initially. Those who moved from semaglutide to tirzepatide lost more weight than those who continued semaglutide. However, among people initially taking tirzepatide, remaining on the medication led to greater weight loss than switching to semaglutide. What Happens To Blood Sugar And Blood Pressure After Stopping?Also read: Stopping Ozempic or Wegovy May Double Your Risk Of Heart Attack, DeathNot just weight loss, the findings also covered metabolic outcomes as patients with existing health conditions also showed significant differences.Among participants with type 2 diabetes, bariatric surgery proved to drive major improvement in HbA1c. This was followed by switching between semaglutide and tirzepatide, continuing the original medication and moving to another obesity drug.Patients with hypertension who continued treatment also experienced greater reductions in blood pressure than those who stopped.Those who discontinued treatment without another intervention showed the smallest improvements in blood glucose control and blood pressure. Why Do People Stop Taking Weight-Loss Injections? GLP-1 medications have become increasingly popular for managing diabetes and combating obesity, but long-term treatment can be difficult for some patients to maintain. Cost, insurance and side effects are among the reasons why people may discontinue these medicines. Gastrointestinal symptoms like nausea, vomiting, diarrhoea and constipation can also affect adherence to treatment.People who cannot continue their original medication, and are considering switching to another treatment or considering bariatric surgery should discuss their options with their healthcare providers.Lead author Hamlet Gasoyan, a researcher at Cleveland Clinic's Center for Value-Based Care Research, said, “The encouraging news is that, for patients who need to stop their injectable GLP-1 medication, it does not mean that their obesity treatment journey has to end.”Co-author Ali Aminian, director of Cleveland Clinic's Bariatric and Metabolic Institute, added, “When a patient stops a GLP-1 medication, the most important question is what comes next.”He noted that patients who stopped all treatment had the least weight loss while those who moved on to another therapy, particularly bariatric surgery, did significantly better.